Venus Remedies Limited, among the world’s leading fixed-dosage injectable manufacturers, has secured marketing authorization from Argentina’s national regulatory authority for its antibiotic, Ceftriaxone. 

The approval marks a significant milestone in the company’s expansion across Latin America, strengthening its growing international portfolio and taking the total marketing authorizations (MAs) for Ceftriaxone to 39 globally. 

The development further reinforces Venus Remedies’ commitment to improving access to essential anti-infective therapies while supporting India’s growing role as a reliable supplier of high-quality injectable pharmaceuticals worldwide.

Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, said, “The approval of Ceftriaxone in Argentina represents an important step in strengthening our presence in the Latin American region. Ceftriaxone remains a cornerstone antibiotic in the management of several serious bacterial infections, including meningitis, respiratory tract infections, bloodstream infections, and surgical infections, making it a critical therapy in hospital and intensive care settings. This authorization aligns with our focus on delivering clinically relevant and widely accessible anti-infective therapies across global markets.”

 The overall Latin American pharmaceutical market is estimated at nearly US$91.85 billion in 2024, projected to reach US$ 172.71 billion by 2034, showing a healthy CAGR of 6.52% across the forecast years.

Aditi K. Chaudhary, President, International Business, Venus Remedies Limited, said, “Securing this marketing authorization in Argentina is a strategically important milestone in our Latin America expansion journey. India exported approximately US$17.5 million worth of pharmaceutical products to Argentina in 2024, while Latin America and the Caribbean accounted for 6.69% of India’s total pharma exports in FY 2024–25. At Venus Remedies, we remain focused on strengthening our presence in such high-potential markets while supporting the broader agenda of improving access to affordable and quality healthcare solutions globally.”